Stock Events

Stock Events

Altimmune 

€2.69
0
-€0.05-1.82% Today

Statistics

Day High
2.75
Day Low
2.68
52W High
7.5
52W Low
2.32
Volume
0
Avg. Volume
864
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q4 2025
Next
-0.23
-0.22
-0.21
-0.2
Expected EPS
-0.205430511
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 3G0.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Novavax
NVAX
Mkt Cap1.32B
Novavax is a direct competitor in the development of vaccines for infectious diseases, similar to Altimmune's focus area.
Moderna
MRNA
Mkt Cap20.21B
Moderna is involved in mRNA-based vaccines and therapeutics, competing in the same innovative vaccine technology space as Altimmune.
BioNTech
BNTX
Mkt Cap24.15B
BioNTech competes with Altimmune in the development of vaccines, including their work on COVID-19 vaccines.
Pfizer
PFE
Mkt Cap153.13B
Pfizer, through its partnership with BioNTech and other vaccine initiatives, is a major competitor in the vaccine market.
Johnson & Johnson
JNJ
Mkt Cap574.66B
Johnson & Johnson, with its global reach and vaccine development, competes in the same space as Altimmune.
Inovio Pharmaceuticals
INO
Mkt Cap86.49M
Inovio Pharmaceuticals is focused on DNA medicines, including vaccines, making it a competitor in the innovative vaccine development space.
GSK
GSK
Mkt Cap116.3B
GlaxoSmithKline, with its extensive vaccine portfolio, is a significant competitor in the global vaccine market.
Sanofi
SNY
Mkt Cap113.88B
Sanofi is involved in vaccine development and distribution, making it a competitor in the global vaccine and immunotherapy market.

About

Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Show more...
CEO
Mr. Jerome Benedict Durso
Employees
57
Country
United States
ISIN
US02155H2004

Listings

STU
DE
3G0.STU
F
DE
3G0.F
MU
DE
3G0.MU
MX
MX
ALT1.MX

0 Comments

Share your thoughts

FAQ

What is Altimmune stock price today?▼
The current price of 3G0.STU is €2.69 EUR — it has decreased by -1.82% in the past 24 hours. Watch Altimmune stock price performance more closely on the chart.
What is Altimmune stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Altimmune stocks are traded under the ticker 3G0.STU.
Is Altimmune stock price growing?▼
3G0.STU stock has fallen by -8.05% compared to the previous week, the month change is a -11.94% fall, over the last year Altimmune has showed a -33.7% decrease.
When is the next Altimmune earnings date?▼
Altimmune is going to release the next earnings report on May 07, 2026.
What were Altimmune earnings last quarter?▼
3G0.STU earnings for the last quarter are -0.23 EUR per share, whereas the estimation was -0.2 EUR resulting in a -15.38% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Altimmune have?▼
As of April 14, 2026, the company has 57 employees.
In which sector is Altimmune located?▼
Altimmune operates in the Health & Wellness sector.
When did Altimmune complete a stock split?▼
Altimmune has not had any recent stock splits.
Where is Altimmune headquartered?▼
Altimmune is headquartered in Gaithersburg, United States.